Loading...
XKRX002620
Market cap88mUSD
Jan 08, Last price  
8,360.00KRW
1D
1.70%
1Q
-5.54%
Jan 2017
-89.64%
Name

Jeil Pharma Holdings Inc

Chart & Performance

D1W1MN
XKRX:002620 chart
P/E
—
P/S
0.16
EPS
—
Div Yield, %
0.88%
Shrs. gr., 5y
24.23%
Rev. gr., 5y
41.30%
Revenues
804.04b
+1.40%
305,027,902,000319,439,855,000369,486,923,000431,307,030,000462,853,352,250426,819,209,150451,968,239,010512,736,239,000594,715,654,750617,279,880,00044,440,576,950142,736,342,500731,140,379,690761,996,752,120762,568,056,300792,964,733,250804,043,001,730
Net income
-16.25b
L-80.46%
13,674,013,00017,534,823,00027,998,250,00025,470,200,00027,014,788,16011,171,837,550484,386,2902,095,459,4109,761,370,9207,890,255,020518,816,621,7207,069,964,240-95,854,011,08011,431,125,930-12,870,005,190-83,145,006,100-16,249,744,230
CFO
-4.42b
L-78.77%
15,672,028,000-132,582,00040,405,855,00019,739,330,00025,665,564,000-3,942,836,01012,915,736,800-3,783,105,0602,743,173,86011,355,091,0005,923,126,290-3,432,762,67025,215,757,600-23,671,463,38013,403,077,570-20,802,154,890-4,415,630,239
Dividend
Dec 27, 202350 KRW/sh
Earnings
Feb 18, 2025

Profile

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. Jeil Pharma Holdings Inc was founded in 1959 and is headquartered in Seoul, South Korea.
URL
https://www.jeilph.co.kr:441/jeilpharmmar/
IPO date
Jan 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
804,043,002
1.40%
792,964,733
3.99%
Cost of revenue
783,122,815
733,480,252
Unusual Expense (Income)
NOPBT
20,920,186
59,484,482
NOPBT Margin
2.60%
7.50%
Operating Taxes
(740,818)
(715,620)
Tax Rate
NOPAT
21,661,004
60,200,102
Net income
(16,249,744)
-80.46%
(83,145,006)
546.04%
Dividends
(1,133,875)
(1,474,876)
Dividend yield
Proceeds from repurchase of equity
(396,983)
BB yield
Debt
Debt current
202,444,469
119,087,349
Long-term debt
13,603,663
19,346,192
Deferred revenue
Other long-term liabilities
15,859,082
34,148,028
Net debt
(43,012,549)
17,912,105
Cash flow
Cash from operating activities
(4,415,630)
(20,802,155)
CAPEX
(9,836,628)
(21,410,039)
Cash from investing activities
(13,425,021)
(17,563,733)
Cash from financing activities
20,616,065
44,913,983
FCF
(28,914,459)
64,809,686
Balance
Cash
59,130,986
53,402,676
Long term investments
199,929,696
67,118,759
Excess cash
218,858,531
80,873,199
Stockholders' equity
135,610,275
414,730,088
Invested Capital
496,577,387
508,471,821
ROIC
4.31%
11.05%
ROCE
3.12%
9.52%
EV
Common stock shares outstanding
15,351
15,351
Price
Market cap
EV
EBITDA
33,476,297
70,389,536
EV/EBITDA
Interest
10,672,114
5,952,288
Interest/NOPBT
51.01%
10.01%